Business
AquaBounty historically pursued genetically engineered Atlantic salmon production, but sold key farms, IP, and assets and now primarily has the Ohio Farm Project asset path to resolve.
AquaBounty had no standard revenue row in FY2025, narrowed its net loss, but ended with negative equity.
The read at a glance✓ Audited against SEC data
- Business mix — Aquaculture asset wind-downWatch
- Revenue — No standard revenue rowNote
- Profitability — Net loss narrowed to $18.5MNote
- Cash — FCF improved to negative $11.7MNote
- Balance sheet — Equity fell negativeWatch
- Insiders — 0 buys / 0 sellsNote
- Accounting — Latest forensic year Altman-Z greyNote
Where the revenue comes from
Fiscal 2023, as AQUABOUNTY TECHNOLOGIES INC reports it. History and quarterly detail are in the app.
- Ge Atlantic Salmon$2.3M
- Non Ge Atlantic Salmon Fry$123K
- Other Revenue$17K
- Non Ge Atlantic Salmon Eggs$730
Leadership changes
From AQUABOUNTY TECHNOLOGIES INC's own filings, the day they're filed.
- Angela Olsen · Chief Compliance Officer · departureeff. 2025-08-22
- David Frank · Chief Executive Officer · departureeff. 2024-12-06
- David Melbourne · Chief Executive Officer · departureeff. 2024-12-06
Latest filings
- 10-Q · Quarterly report2026-08-06
- 8-K · Company announcement2026-08-06
- 8-K · Company announcement2026-07-08
- 8-K · Company announcement2026-06-30
- 8-K · Company announcement2026-06-25
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about AQUABOUNTY TECHNOLOGIES INC, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.